Neurocrine Biosciences, Inc. announced the publication of a classic congenital adrenal hyperplasia (CAH)-focused supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM). The supplement, titled 'Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime,' contains eight review articles.
These articles provide a comprehensive look at the clinical, psychosocial, treatment-related, and day-to-day challenges faced by individuals with classic CAH. The reviews explore various aspects of CAH management, including pathophysiology, clinical manifestations, treatment challenges, barriers to care, psychosocial impact, and advances in treatment, including CRENESSITY.
The supplement aims to provide healthcare professionals with up-to-date insights and evidence-based approaches to enhance clinical practice and patient care. This initiative underscores Neurocrine's commitment to empowering patients, caregivers, and healthcare providers with knowledge about CAH and emerging treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.